Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Organoid profiling identifies common responders to chemotherapy in pancreatic cancer

ABSTRACT: Organoid profiling identifies common responders to chemotherapy in pancreatic cancer

PROVIDER: PRJNA473873 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Organoid profiling identifies common responders to chemotherapy in pancreatic cancer

Project description:Organoid profiling identifies common responders to chemotherapy in pancreatic cancer

| PRJNA473874 | ENA

Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer.

Project description:Pancreatic cancer is the most lethal common solid malignancy. Systemic therapies are often ineffective, and predictive biomarkers to guide treatment are urgently needed. We generated a pancreatic cancer patient-derived organoid (PDO) library that recapitulates the mutational spectrum and transcriptional subtypes of primary pancreatic cancer. New driver oncogenes were nominated and transcriptomic analyses revealed unique clusters. PDOs exhibited heterogeneous responses to standard-of-care chemotherapeutics and investigational agents. In a case study manner, we found that PDO therapeutic profiles paralleled patient outcomes and that PDOs enabled longitudinal assessment of chemosensitivity and evaluation of synchronous metastases. We derived organoid-based gene expression signatures of chemosensitivity that predicted improved responses for many patients to chemotherapy in both the adjuvant and advanced disease settings. Finally, we nominated alternative treatment strategies for chemorefractory PDOs using targeted agent therapeutic profiling. We propose that combined molecular and therapeutic profiling of PDOs may predict clinical response and enable prospective therapeutic selection.Significance: New approaches to prioritize treatment strategies are urgently needed to improve survival and quality of life for patients with pancreatic cancer. Combined genomic, transcriptomic, and therapeutic profiling of PDOs can identify molecular and functional subtypes of pancreatic cancer, predict therapeutic responses, and facilitate precision medicine for patients with pancreatic cancer. Cancer Discov; 8(9); 1112-29. ©2018 AACR.See related commentary by Collisson, p. 1062This article is highlighted in the In This Issue feature, p. 1047.

| S-EPMC6125219 | biostudies-literature

Bulk RNAseq of AB1-HA murine mesothelioma tumors from complete responders and partial responders to cyclophosphamide chemotherapy

Project description:Purpose: To compare the gene expression profiles of tumors from complete responders and partial responders to cyclophosphamide chemotherapy. AB1-HA murine mesothelioma tumors were excised one day prior to cyclophosphamide or three or seven days post cyclophosphamide.

2022-08-18 | GSE182674 | GEO

Single-cell transcriptome profiling of primary tumors and paired organoids of pancreatic cancer

Project description:Pancreatic cancer (PC) is the most lethal common gastrointestinal malignancy with an overall 5-year survival rate of 11%. Recently, a variety of patient-derived models, including patient-derived xenograft (PDX) and cancer organoid models, have paved a way for identifying common responders to chemotherapy. However, the utility of PC organoid for recapitulating hallmarks of corresponding primary tumor at transcriptome level remains to be investigated. We conducted single-cell RNA sequencing (scRNA-seq) for three paired primary tumors and organoids using the 10x Genomics platform to identify common and different phenotypes between them.

2022-10-04 | GSE214295 | GEO

TCR sequencing data from responders and progressors to cyclophosphamide chemotherapy

Project description:TCR sequencing data from responders and progressors to cyclophosphamide chemotherapy

| PRJNA893623 | ENA

Bulk RNAseq of AB1-HA murine mesothelioma tumors from complete responders and partial responders to cyclophosphamide chemotherapy

Project description:Bulk RNAseq of AB1-HA murine mesothelioma tumors from complete responders and partial responders to cyclophosphamide chemotherapy

| PRJNA757407 | ENA

Gene profile for chemotherapy response in head and neck carcinoma

Project description:Transcriptional profiling was performed on biopsies from patients with head and neck squamous cell carcinoma that had been treated with cisplatin and 5-fluorouracil to identify genes predictive of response to chemotherapy Two condition experiment, Biopsies from complete clinical responders and from non-responders were compared based upon a common reference using a two color design

2013-10-06 | E-GEOD-32877 | biostudies-arrayexpress

TCR sequencing data from responders and progressors to cyclophosphamide chemotherapy

Project description:The difference in the TCR between responders and progressors to cyclophosphamide is unknown. Here we performed TCR sequencing on the RNA of tumors from mice bearing AB1-HA. Mice were catagorised as responders and non-responders.

2022-10-27 | GSE216443 | GEO

A223 bintrafusp alfa non-responders and responders

Project description:A223 bintrafusp alfa non-responders and responders

| PRJNA677973 | ENA

Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant ChemotherapyIdentification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy

Project description:Neoadjuvant chemotherapy (NAC) has been of recent interest as an alternative to upfront surgery followed by adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC). However, a subset of patients does not respond to NAC and may have been better managed by upfront surgery. Hence, there is an unmet need for accurate biomarkers for predicting NAC response in PDAC. This project aimed to identify upregulated proteins in tumor tissue from poor- and good-NAC responders.

2020-04-16 | PXD017051 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data